our to today's their for analysts Thanks interest and and Brian. call. in investors for Kamada you, participating also Thank in
equity million Israel Earlier Opportunity private an to FIMI firm we off placement start We are private shareholder. significant $XX a Kamada and and XXXX, an excellent strategic in leading existing Funds, today, financially in announced a both operationally. with
of additional we with in we'll the shortly, Kamada's financing confidence but quality FIMI has indicative potential. high view say in detail significant this upfront from are that investor I investment we as growth and will this it discuss this thrilled substantial further
increase $XX.X quarter in total achieved of the begin quarter quarter Let compared year million, of growth of growth in the business financial begin first the of with an first us anticipated though just year-over-year the results, with. and which X% to to EBITDA of XX% We top with revenue line bottom represented million, our as XXXX. and impressive our first $X.X
continue business. growth sales the HEPAGAM, CYTOGAM, and US, multiple drivers, full to which acquired and XXXX, effectively the we late portfolio WINRHO, approved Importantly, of leverage KEDRAB Immune internationally, Israeli in are including distribution the FDA our marketed in Globulin VARIZIG
year. first extend compared ahead, XXXX, Looking enhanced we the the further with meaningfully from to momentum last throughout quarter to to be expect profitability
$XXX of XX% approximately represent XXXX are As our full-year range and $XX million. over million to such, XXXX. we guidance that million The revenue EBITDA profitability growth reiterating will midpoint $XX of to of $XXX million of
ahead upside the years XXXX, Beyond growth double-digit revenue of anticipate to potential continue we in downside and limited us, risk. foreseeable with and significant profitability annual
purchase XX.X agreement, within the officially Our recently the key the a transaction, of purchase agreement. represents $X.XX ordinary of we completion the to the shares the of the of price shareholder with company is XX% importantly, of FIMI price which issue to FIMI average company on days shares agreement ordinary FIMI Law. will meaning Kamada own become purchase of expected during share, the a closing of prior prospects were further the entered a shares Kamada million Israeli per Companies date outstanding approximately of NASDAQ the the trading of controlling private the Upon multiple successful terms shares of and XX at a Under achievements. significantly purchase into with to the million placement. ordinary in aggregate to securities $XX enhanced approximately an will Most closing
opportunities. existing with provides This business growth our accelerate to business of allowing development us us the compelling flexibility, financial investment and strategic pursue
grateful are position shown forward going the FIMI forward. to strengthened significantly for support cash we by leveraging and continued our look We
approve second will company extraordinary results. shareholders the of XXXX private the issuance the placement our quarter of of be general financial XXXX held meeting An to following in the August
were CYTOGAM existing month earlier FDA the we to respect facility With this approval Beit our to at pleased Israel. receive to business, Kama, in manufacture
previous timeline, the With granted Behring. process within the was CYTOGAM which approval, FDA of from the transfer for the expected successful conclusion represented technology CSL the manufacturer,
like four and since commercial by in product acquired facility our CYTOGAM highlight Israeli will selling generating margins facility. over KEDRAB, utilization third We of by I the in of be which manufacturing in initiated product, the is $XX CYTOGAM to to XXXX, approximately XX%. in efficiency. XXXX, for our positively addition Kamada impact and approved to November the have the Immune and highest is gross million that sales at maintained manufacturing, FDA would it Globulin GLASSIA
is for milestone Swissmedic GLASSIA of of Switzerland in in half alpha-X GLASSIA therapy commercial to representing the a due to during product significant annually. the of year country and maintenance required this Switzerland Kamada upon market clinically reimbursement Also adults emphysema note, chronic which launch recently the $XX The in augmentation expected authorization Switzerland alpha-X is is for estimated marketing million second coverage. over currently to severe obtaining a for occur approve the granted European in for evident deficiency, deficiency. with be to
focused patients, for eligible medicines partnered To specialty a Group, with across commercialization diseases Hydrogen company rare ensure of the Europe. wide on we've access the to
were its of of focused and expanding international are Outside of commercialization markets. further the US, the XXXX revenue to and we approximately product on sales million the the annual $X in GLASSIA
the continued since gain share which is in the products what of Kamada. several reiterate US months, I be substantially few move Let's over of advantages leveraging globulin especially as Also, KEDRAB some the market, Kedrion, will in be rabies product said available we've to clinically human highlight annually. KEDRAB significantly to margin more $XXX immune studied team and immune generates to next US our years. the anticipate is to previously, XX% the than the in as over to only on marketed the We should children. has grow from grow continue KEDRAB, that this product to beginning of US the year, commercial successfully that gross estimated the in million rabies In globulin. the the past to and
our progress specialty making in XXXX promoting US is physician meetings. Additionally, established portfolio excellent our other and engagement our team through direct to IgG at during practitioners medical and healthcare opportunities
first our reminder, been activity products decade a hyper-immune the in this supported of CYTOGAM particularly the have a by this and field represents As specialty US. activities important therapy, promoting VARIZIG, that time based
data activity medicines, and on to demand in impact educational to believe symposiums the started impact demand. portfolio feedback growth product, expanding contributing this our seeking a will to of positive for conducting that of are are the by increased in opinion from see positive who to while seeing expect have continued the leaders received products we ahead. key We the encouraged these new consistently We've quarters clinical publish related of
ahead company. Moving on, Kamada future with looking plasma Plasma, progress US-based we catalysts, are further at collection pleased our the by made
of a product and XXXX represented entry Texas US acquisition the becoming supported plasma specialty company. collection Houston, integrated goal center plasma in of plasma market strategic collection fully Our Kamada's our the into
are premium plasma. plasma actively regular center further in our to collection of capacity We first supply enhance are high at the centers expanding successfully normal and additional to advancing US open specialty the our plan our and
recommended the InnovAATe achieved recently Data therapy an our in are the alpha-X trial side, development inhaled Safety ongoing by Monitoring we XX independent enrolled X for modification without progress most alpha-X study study the patients treatment Board deficiency. the since recent the clinical to Phase of study time encouraged initiated. The for pivotal for On the antitrypsin has date, was fifth continuation
the progress to with few pathway. them and and expedite potential to opportunities trial In show continue the to the intend regulatory study weeks, FDA Medicines We European next discuss Agency to we'll recruitment. meet
already As we've substantial over a a a in said in market product for sales to annual that opportunity the exists $X US inhaled Europe. billion transformation in previously, and alpha-X be is
I you share exciting first I'd Before some to financial news. our quarter additional read results, like
Orlev, FIMI, the remain his to maximizing he million to be out will our supporting has resignation $XX the private his placement. strategic the had other and Kamada's previously CFO position opportunities, withdrawn XXXX continued by instrumental Kamada's investment opportunities in CFO, has planned in served Chaime December and Chaime transition and pursue since of growth who provided position. his Following will from
who Kamada as In rejoined previously XXXX, General our Counsel Vice Livneh, served as and addition, Nir XXXX Corporate President, has until Counsel Secretary. General and Corporate from Secretary
specialty will plasma Both they industry. Chaime and as the team, Nir global role significantly strengthen advancement our play a a executive our in leader further in management and pivotal
strong in first XXXX. approximately Israeli globulin of during immune million, $XX.X With X% driven sales quarter million quarter The our product, first quarter now increase $XX.X quarter the the revenues previously growth our the were first from discuss that, the was primarily the by the of first financial for KEDRAB, and Total I'll a of contribution year-over-year recorded sales. results. distribution acquired
first XXXX quarter XXXX. of the was the for XX% million, XX% profit quarter first gross $XX.X million compared $XX.X in margin to of margin or Total representing
now to our Let's depreciation the turn expenses. explanation of
with the XXXX of which was associated As previously expenses the accounting intangible acquisition for products. through assets, depreciation IgG late discussed, generated company's our
XX%, and would the of gross quarter depreciation, respectively, million the and million first respectively, Gross this compared first profit quarter of excluding margins, have year XX%, XXXX. in $XX.X asset been in to $XX.X such and intangible
of this to the R&D, first $XX.X in million marketing, compared sales and first in G&A, quarter and million expenses, XXXX. Operating expenses, other the including totaled of $XX.X quarter year
costs acquisition. of the Sales product and included million intangible first IgG for the assets depreciation expenses marketing generated $X.X quarter through of
workforce plant, level XXXX, During quarter the we of first capacity. Israeli at to optimizing the conducted staff downsizing planned
$X.X X% in result The overall were expected employees a to approximately of severance is As planned labor in reduction annualized a million laid compensation this an exit of to result incurred the expense of downsizing Israeli for we downsizing, provided off. cost. who
compared InnovAATe year G&A, we activities, We overall and between during XX% as our as X advance to our last well commercial operation including sales continue and trial. marketing R&D, continue XX% XXXX increase to to expenses, as Phase our to to expect as
reevaluation As the we long-term assumed consideration liability, throughout in to continue to account of contingent the are acquisition to did completed respect XXXX, with the of related financing for expenses XXXX. which all and we
For finance charges of quarter million. first totaled these $X.X XXXX, the
Net of with approximately million basis, XXXX or the $X.X period. for share fully loss diluted third prior-year consistent the was quarter per on a $X.XX
product, the intangible depreciation $X.XX or assumed of per of the associated finance XXXX. in of company contingent recorded of would with net liabilities first the the acquired expenses and million and the $X.X consideration have other share Excluding quarter income long-term expenses assets
to was quarter EBITDA XXXX quarter the $X.X a representing of year-over-year. million compared the first increase XX% third in significant million for XXXX, as $X.X of
million have a representing XXXX, the exit significant employees the million severance who $X.X would of laid $X.X quarter increase were expense XX% the paid been of off, first in Excluding compensation EBITDA to the year-over-year.
million $XXX million and our earlier, midpoint guidance reiterating I million. As guidance of range compared to $XX of XX% full-year $XXX $XX EBITDA to such year The XXXX. the as we of represents highlighted revenue are approximately XXXX growth million fiscal to
was XXXX cash million $X.X XXXX. used first $X.X the million to compared Finally, quarter of as cash operating in quarter first operating activities of provided activities the by of in in
total was $XX XXXX as as cash XX, half close $XX.X of to this of announced $XX.X as net XXXX. of is in of the for to This include million which year. does expected March second million the end recently Our million not financing, expected position compared proceeds the figure
concludes That remarks. our prepared
for open now will We the Operator? questions. call
